Charles Schwab Investment Management Inc. Grows Stock Position in 10x Genomics $TXG

Key Points

• Charles Schwab Investment Management Inc. increased its stake in 10x Genomics by 20.2%, holding 648,410 shares worth approximately $5.66 million as of the end of the first quarter.
• Insider transactions revealed that Benjamin J. Hindson and CFO Adam Taich both sold shares, reducing their ownership by 1.67% and 6.73% respectively.
• 10x Genomics reported a significant earnings beat, posting $0.28 EPS for the last quarter, compared to an expected loss of ($0.35), and achieved a revenue of $172.91 million.

Charles Schwab Investment Management Inc. increased its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 20.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 648,410 shares of the company's stock after acquiring an additional 108,744 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.53% of 10x Genomics worth $5,661,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in 10x Genomics in the fourth quarter valued at about $32,000. GAMMA Investing LLC lifted its stake in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after buying an additional 1,614 shares during the period. Signaturefd LLC increased its holdings in shares of 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after acquiring an additional 2,409 shares in the last quarter. Whittier Trust Co. purchased a new stake in 10x Genomics in the 1st quarter valued at $41,000. Finally, PNC Financial Services Group Inc. lifted its stake in 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after acquiring an additional 3,119 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. The Goldman Sachs Group dropped their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research report on Monday, May 12th. Bank of America raised their price target on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Morgan Stanley reduced their price objective on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research report on Monday, August 11th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics has an average rating of "Hold" and a consensus price target of $13.54.

10x Genomics Price Performance

Shares of TXG traded down $0.27 during trading hours on Monday, hitting $14.01. The stock had a trading volume of 1,566,109 shares, compared to its average volume of 3,022,419. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $24.76. The firm has a market capitalization of $1.74 billion, a PE ratio of -20.01 and a beta of 2.00. The stock has a fifty day moving average price of $12.92 and a 200 day moving average price of $10.68.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business's revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Activity

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares of the company's stock, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,149 shares of company stock valued at $539,865. 10.03% of the stock is currently owned by insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.